Home / Recalls / Baxter Healthcare Corporation / Z-1280-2018

Z-1280-2018 Class II Terminated

Recalled by Baxter Healthcare Corporation — Deerfield, IL

FDA device recall Z-1280-2018 was initiated by Baxter Healthcare Corporation on Feb 15, 2017 and is designated Class II. Reason for recall: Firm has received reports of device operators failing to adhere to instructions for use pertaining to the safe unloading of disposable sets from the Prismaflex Control Unit. Additionally, for software… The recall status is terminated (terminated May 8, 2019). Affected quantity: 3,440 units.

Recall details

Product Type: Devices
Report Date: Apr 11, 2018
Initiation Date: Feb 15, 2017
Termination Date: May 8, 2019
Voluntary/Mandated: Voluntary: Firm initiated
Product Quantity: 3,440 units

Product description

Prismaflex Control Unit. Dialyzer, high permeability with or without sealed dialysate system. Continuous Renal Replacement Therapy (CRRT) for patients weighing 20 kilograms or more with acute renal failure and/or fluid overload. *Therapeutic Plasma Exchange (TPE) therapy for patients weighing 20 kilograms or more with diseases where removal of plasma components is indicated.

Reason for recall

Firm has received reports of device operators failing to adhere to instructions for use pertaining to the safe unloading of disposable sets from the Prismaflex Control Unit. Additionally, for software versions 5.10 and 6.10, the programmed syringe size for the syringe pump may revert to safe default values unintentionally.

Distribution pattern

Worldwide Distribution - USA (nationwide) Distribution and to the countries of : Algeria, Armenia, Australia, Bahrain, Belarus, Belgium, Canada, China, Cyprus, Denmark, Egypt, France, Germany, Great Britain, Greece, Ireland, Italy, Albania, Bulgaria, Croatia, Czech Republic, Estonia, Hong Kong, Hungary, Iceland, India, Iran, Israel, Ivory Coast, Jordan, Kazakhstan, Kenya, Kosovo, Kuwait, Latvia, Lebanon, Libya, Lithuania, Macedonia, Malaysia, Malta, Montenegro, Morocco, Netherlands, New Zealand, Nigeria, Norway, Pakistan, Poland, Portugal, Qatar, Romania, Russia, Saudi Arabia, Serbia, Singapore, Slovakia, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Syria, Taiwan, Thailand, Tunisia, Turkey, United Arab Emirates, Ukraine, Vietnam, Yemen, Argentina, Brazil, Chile, and Dominican Republic

Code information

Product code: 6023014700, 107493, 113081, 115269; Serial Number: All; Affected Software Versions: SW 4.1x, 5.10, 6.10, 7.xx, 8.00

Source

Dataset: openFDA device recall enforcement reports
FDA record: This recall in openFDA (JSON)
Enforcement Report: Search FDA's Enforcement Report for Z-1280-2018
openFDA file date: Nov 10, 2026
Loaded by RegDataLab: Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Other recalls by Baxter Healthcare Corporation

Z-0151-2027 Class II — Likorall Overhead Lifts Product Code: 3121001 Product Description: LIKORALL… (Sep 14, 2026)
Z-3263-2026 Class II — PRO+ 36" MRS SURFACE, mattress with Advanced Microclimate Technology (AMT) uses… (Aug 18, 2026)
Z-3264-2026 Class II — PRO+ 40" MRS SURFACE, mattress with Advanced Microclimate Technology (AMT) uses… (Aug 18, 2026)
Z-3262-2026 Class II — PRO+ MRS SURFACE FOR VERSACARE, mattress with Advanced Microclimate Technology… (Aug 18, 2026)
D-0850-2026 Class I — Dextrose Injection, USP, 70 %, 2000 mL bags, Rx Only, Baxter Healthcare… (Aug 17, 2026)
D-0849-2026 Class I — 0.9% Sodium Chloride Injection USP 500 mL, VIAFLEX Plastic Containers, with 24… (Aug 17, 2026)
Z-3065-2026 Class II — Baxter Novum IQ Syringe Pump, Model Number 40800BAXUS (Aug 11, 2026)
Z-3066-2026 Class II — Baxter Novum IQ Syringe Pump, Loaner, Model Number 40800BAXUSL (Aug 11, 2026)
D-0817-2026 Class II — Clindamycin Injection USP in 5% Dextrose, 900 mg/50 mL (18 mg/mL), in GALAXY 50… (Aug 6, 2026)
D-0806-2026 Class II — MYXREDLIN, Insulin Human in 0.9% Sodium Chloride Injection, 100 units/100 mL (1… (Aug 6, 2026)